| Literature DB >> 31849436 |
Veena Iyer1, Anal Ravalia1, Kankshi Bhavsar1, Susanna Abraham Cottagiri1, Ayushi Sharma1, Mahendra Vegad2, Parul Shah3, Bhavini Shah4, Bhavin Solanki5, Sumeeta Soni2, Dileep Mavalankar1.
Abstract
INTRODUCTION: India possibly carries the highest burden of antimicrobial resistant typhoidal salmonellae in the world. We report on the health-care ecosystem that produces data on antimicrobial resistance (AMR) testing and the resistance patterns of typhoidal Salmonella isolates in the city of Ahmedabad.Entities:
Keywords: Ahmedabad; antimicrobial resistance; antimicrobial resistance in Salmonella; antimicrobial-resistance surveillance; regional antimicrobial-resistant pattern; typhoidal Salmonella
Year: 2019 PMID: 31849436 PMCID: PMC6906890 DOI: 10.4103/jgid.jgid_149_18
Source DB: PubMed Journal: J Glob Infect Dis ISSN: 0974-777X
Figure 1Filtering of diagnostic laboratory services in Ahmedabad to detect facilities with culture and antibiotic sensitivity testing capacity
Overview of resistance
| Laboratories | Period | Number of blood samples cultured | AST done | Resistant isolates (%) | Resistance to 1 antibiotic | Resistance to >1 antibiotic | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | |||||||||||
| MC1 | May 11-October 15 | 34,748 | 42 | 40 | 32 | 8 | 19 (48) | 6 | 0 | 10 | 3 |
| MC2 | January 14-December 15 | 10,232 | 55 | 40 | 36 | 4 | 4 (10) | 2 | 0 | 1 | 1 |
| CL | January 14-December 15 | 6640 | 44 | 44 | 40 | 4 | 44 (100) | 0 | 0 | 40** | 4** |
| Total | 55 months | 51,620 | 141 | 124 | 108 | 16 | 67 (54) | 8 | 0 | 51 | 8 |
**All 44 isolates from private CL and one each from MC1 and MC2 were resistant to at least 18 antibiotics, S. typhi: Salmonella typhi S. paratyphi: Salmonella paratyphi, CL: Corporate laboratory, AST: Antibiotic sensitivity testing
Antibiotic resistance pattern
| Antibiotics | MC1 | MC2 | CL | Total | ||||
|---|---|---|---|---|---|---|---|---|
| Total | Total | |||||||
| Total isolates ( | 32 | 8 | 36 | 4 | 40 | 4 | 108 | 16 |
| Ampicillin | 1/16 (6.25) | 0/3 (0) | 1/30 (3) | 0/4 (0) | 4/33 (12) | 0/4 (0) | 6/79 (7.59) | 0/11 (0) |
| Chloramphenicol | 3/12 (25) | 0/5 (0) | 1/36 (3) | 0/1 (0) | 0/40 (0) | 0/4 (0) | 4/88 (4.54) | 0/10 (0) |
| Nalidixic acid | 0/1 (0) | - | - | - | 38/39 (97) | 4/4 (100) | 38/40 (95) | 4/4 (100) |
| Ciprofloxacin | 8/16 (50) | 0/4 (0) | 1/3 (33) | - | 3/40 (8) | 1/4 (25) | 12/59 (20.33) | 1/8 (12.5) |
| Ceftriaxone | 1/6 (17) | 0/3 (0) | 1/36 (3) | 0/4 (0) | 1/40 (3) | 0/4 (0) | 3/82 (3.65) | 0/11 (0) |
| Cefixime | - | - | 0/3 (0) | - | 1/40 (3) | 0/4 (0) | 1/43 (2.32) | 0/4 (0) |
| Azithromycin | 0/1 (0) | - | - | - | 39/40 (98) | 4/4 (100) | 39/41 (95.12) | 4/4 (100) |
r: Number of isolates resistant, n: Number of isolates tested, S. typhi: Salmonella typhi, S. paratyphi: Salmonella paratyphi, CL: Corporate laboratory